- Home
- PFL vs NGNE Comparison
PFL vs NGNE Comparison
Compare PFL & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFL
- NGNE
- Stock Information
- Founded
- PFL 2003
- NGNE 2003
- Country
- PFL United States
- NGNE United States
- Employees
- PFL N/A
- NGNE N/A
- Industry
- PFL Finance Companies
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- PFL Finance
- NGNE Health Care
- Exchange
- PFL Nasdaq
- NGNE Nasdaq
- Market Cap
- PFL 374.5M
- NGNE 317.5M
- IPO Year
- PFL N/A
- NGNE N/A
- Fundamental
- Price
- PFL $8.33
- NGNE $22.72
- Analyst Decision
- PFL
- NGNE Strong Buy
- Analyst Count
- PFL 0
- NGNE 7
- Target Price
- PFL N/A
- NGNE $41.86
- AVG Volume (30 Days)
- PFL 113.7K
- NGNE 213.6K
- Earning Date
- PFL 01-01-0001
- NGNE 08-08-2025
- Dividend Yield
- PFL 11.53%
- NGNE N/A
- EPS Growth
- PFL N/A
- NGNE N/A
- EPS
- PFL N/A
- NGNE N/A
- Revenue
- PFL N/A
- NGNE $925,000.00
- Revenue This Year
- PFL N/A
- NGNE N/A
- Revenue Next Year
- PFL N/A
- NGNE N/A
- P/E Ratio
- PFL N/A
- NGNE N/A
- Revenue Growth
- PFL N/A
- NGNE N/A
- 52 Week Low
- PFL $6.98
- NGNE $6.88
- 52 Week High
- PFL $8.62
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- PFL 54.51
- NGNE 60.64
- Support Level
- PFL $8.31
- NGNE $20.80
- Resistance Level
- PFL $8.35
- NGNE $23.88
- Average True Range (ATR)
- PFL 0.05
- NGNE 1.44
- MACD
- PFL 0.00
- NGNE 0.09
- Stochastic Oscillator
- PFL 52.58
- NGNE 72.83
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.